<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary hyperoxaluria</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary hyperoxaluria</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary hyperoxaluria</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3614771431"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary hyperoxalurias (PHs) are rare inborn errors of glyoxylate metabolism characterized by the overproduction of oxalate, which is poorly soluble and is deposited as calcium oxalate in various organs. In patients with PH, the increased production results in increased urinary excretion of oxalate leading to kidney injury and, in some cases, end-stage kidney failure. The clinical manifestations, diagnosis, and treatment of PH are reviewed here.</p><p class="headingAnchor" id="H1172607311"><span class="h1">GENETICS AND PATHOGENESIS</span></p><p class="headingAnchor" id="H3329075897"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Primary hyperoxaluria (PH) is primarily caused by autosomal recessive variants in three genes that encode enzymes involved in glyoxylate metabolism. These pathologic variants result in enhanced oxalate production  (<a class="graphic graphic_figure graphicRef117739" href="/z/d/graphic/117739.html" rel="external">figure 1</a>). As oxalate is typically excreted in the urine, the kidney is the prime target for excessive oxalate deposition resulting in nephrocalcinosis and kidney stones and, in some cases, end-stage kidney disease (ESKD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PH type 1</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F259900&amp;token=tEpDslnpc0F0kICl%2Fz7sFSLeNgcJq1VeUFL1W5mY%2FuWE0saDF%2BjUOIfN68hRzHPu&amp;TOPIC_ID=6141" target="_blank">MIM #259900</a>) is due to variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a> that encodes the hepatic peroxisomal enzyme alanine glyoxylate aminotransferase (AGT), a pyridoxal 5'-phosphate-dependent enzyme, which is involved in the transamination of glyoxylate to glycine [<a href="#rid1">1</a>]. This inborn error of metabolism leads to an increase in the glyoxylate pool, which is converted by lactate dehydrogenase to oxalate. It is the most common PH type and accounts for approximately 70 to 80 percent of PH cases [<a href="#rid2">2,3</a>]. It is the most severe form of PH, with more rapid progression to kidney dysfunction and the development of ESKD in one-half of patients by young adulthood, historically [<a href="#rid4">4</a>]. (See <a class="local">'Primary hyperoxaluria type 1'</a> below.)</p><p></p><p class="bulletIndent1">The <em>AGXT</em> gene maps to chromosome 2q36-37 and encodes for a 43 kDa protein [<a href="#rid5">5,6</a>]. More than 190 variants have been identified in the <em>AGXT</em> gene, which are found in all 11 exons of the gene [<a href="#rid7">7-10</a>]. The variants, most of which lead to a major or complete loss of enzyme activity, are predominantly single nucleotide substitutions (75 percent) including missense, nonsense, and splice site mutations, and the remaining variants are due to deletions and insertions [<a href="#rid9">9,11</a>].</p><p></p><p class="bulletIndent1">These genetic variants result in three different expressions of AGT protein and its activity [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of both immunoreactive AGT protein and AGT catalytic activity, which occurs in approximately 40 percent of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of immunoreactive AGT protein and absence of AGT catalytic activity, which occurs in approximately 15 percent of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of both immunoreactive AGT protein and AGT catalytic activity, but at levels that are 50 percent below normal values. In these patients, most of the AGT is localized in the mitochondria and not in the peroxisomes (mistargeting phenotype). Four mutations (Gly170Arg, Ile244Thr, Phe152Ile, and Gly41Arg) result in both expression of AGT protein and activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PH type 2</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F260000&amp;token=tEpDslnpc0F0kICl%2Fz7sFVotXPSmMDaW2EHangYam62E6lBubK5KBW%2BPP7SkpEPc&amp;TOPIC_ID=6141" target="_blank">MIM #260000</a>) is due to variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604296&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqP9U0smJv72BxGsqK1Z2uj&amp;TOPIC_ID=6141" target="_blank"><i>GRHPR</i></a> that encodes the cytosolic enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR), which normally converts glyoxylate to glycolate [<a href="#rid12">12</a>]. It accounts for approximately 10 percent of PH cases [<a href="#rid2">2-4</a>]. (See <a class="local">'Primary hyperoxaluria type 2'</a> below.)</p><p></p><p class="bulletIndent1">Unlike the AGT of PH type 1, this enzyme, although predominantly expressed in the liver, has a wide tissue distribution [<a href="#rid13">13</a>]. Pathologic variants of <em>GRHPR</em> result in increased amounts of glyoxylate and hydroxypyruvate, which are converted by lactate dehydrogenase to oxalate and L-glycerate  (<a class="graphic graphic_figure graphicRef117739" href="/z/d/graphic/117739.html" rel="external">figure 1</a>). These metabolites are excreted in excessive amounts in the urine, which in the case of oxalate, leads to recurrent kidney stones.</p><p></p><p class="bulletIndent1">The <em>GRHPR</em> gene maps to chromosome 9p11 and encodes for a 36 kDa protein [<a href="#rid14">14</a>]. More than 40 mutations have been described and include deletions, insertions, missense, and nonsense mutations [<a href="#rid4">4,15</a>]. The most common mutation occurring in approximately 40 percent of cases is a deletion of a single base pair in exon 2 (c.103delG).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PH type 3</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613616&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7rJmj9Txitra4dYcI48vi3&amp;TOPIC_ID=6141" target="_blank">MIM #613616</a>) is due to variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613597&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz69AA%2BsAln8FLKazgoimJem&amp;TOPIC_ID=6141" target="_blank"><i>HOGA1</i></a> that encode the liver-specific mitochondrial 4-hydroxy-2-oxoglutarate aldolase enzyme. This enzyme, expressed in the liver and the kidney, is the final step of the hydroxyproline degradation pathway within the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate  (<a class="graphic graphic_figure graphicRef117739" href="/z/d/graphic/117739.html" rel="external">figure 1</a>) [<a href="#rid16">16,17</a>]. PH type 3 is the mildest form of PH and appears to account for approximately 5 to 10 percent of genetically characterized cases [<a href="#rid2">2-4,18,19</a>]. However, the prevalence of PH type 3 may be greater than previously published clinical studies reported. (See <a class="local">'Primary hyperoxaluria type 3'</a> below and <a class="local">'Epidemiology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Two additional groups of PH patients have also been identified:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eleven percent of families in a study of 355 patients (301 families) registered in the Rare Kidney Stone Consortium PH registry (RKSC PH registry) had a PH phenotype but no variant in any of the three genes associated with PH (<em>AGXT</em>, <em>GrHPR</em>, and <em>HOGA1</em>) [<a href="#rid4">4</a>]. These patients presented between four and nine years of age, had lower urine oxalate excretion than PH types 1 and 2, and did not tend to progress to ESKD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two unrelated patients with calcium oxalate stones and variants in the SAT1 sulfate-oxalate transporter, encoded by <em>SLC26A1</em>, have been reported [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H2378577119"><span class="h2">Genotype/phenotype correlation</span><span class="headingEndMark"> — </span>PH type 1 is the most severe form of PH as patients are more likely to progress to ESKD and do so at an early age [<a href="#rid3">3,4,21,22</a>]. However, patients with PH type 2 may also develop ESKD. Patients with type 3 disease present at an earlier age than those with types 1 and 2 but typically have a lower urinary oxalate production rate and slower decline in kidney function. It remains uncertain whether type 3 disease progresses to ESKD. (See <a class="local">'Primary hyperoxaluria type 3'</a> below.)</p><p>For all three PH types, there is variable expression, even among family members with the same genotype [<a href="#rid4">4</a>]. This was illustrated in one study that reported differences of greater than 20 years in the onset of ESKD between siblings with PH type 1 [<a href="#rid4">4</a>]. In addition, within families with PH types 2, disease expression varies with one affected sibling progressing to ESKD, whereas the other siblings only had occasional symptomatic kidney stones.</p><p>There appears to be a closer correlation between genotype and phenotype for specific mutations of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a> gene. In particular, the most common variant <em>AGXT</em> <em>p</em>.Gly170Arg (reported allelic frequency of 21.5 percent in White patients) is due to a mistargeting allele and results in a milder PH type 1 phenotype [<a href="#rid4">4</a>]. <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Pyridoxine</a> treatment significantly reduces urinary oxalate excretion in patients with this variant, resulting in better long-term outcomes when the diagnosis is made early enough for medical intervention [<a href="#rid21">21,23,24</a>]. A similar positive response to pyridoxine therapy is also seen in patients with <em>AGXT</em> p.Phe152Ile mutations [<a href="#rid25">25</a>]. (See <a class="local">'Medical management'</a> below.)</p><p class="headingAnchor" id="H728503045"><span class="h2">Effects of oxalate deposition</span><span class="headingEndMark"> — </span>The excess oxalate that is produced in PH is primarily excreted by the kidneys. As kidney function declines, plasma oxalate levels increase, and calcium oxalate is deposited into other tissues, resulting in systemic oxalosis and manifestations outside the kidney.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney injury</strong> – The increased urinary excretion of oxalate results in urinary calcium oxalate supersaturation, which leads to crystal aggregation, kidney stones, and/or nephrocalcinosis  (<a class="graphic graphic_picture graphicRef65169" href="/z/d/graphic/65169.html" rel="external">picture 1</a> and <a class="graphic graphic_diagnosticimage graphicRef50463" href="/z/d/graphic/50463.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1">PH type 1 is the most severe form of PH. Patients with PH type 1 have higher urine oxalate levels and higher incidence of nephrocalcinosis than the other two types of PH. In patients with PH type 1, urinary oxalate excretion exceeds 1 mmol/1.73 m<sup>2 </sup>per day (normal &lt;0.5 mmol/1.73 m<sup>2</sup> per day) [<a href="#rid14">14</a>]. The presence of nephrocalcinosis is associated with increased risk for kidney failure, while the number of stones and stone events are not significantly associated with a risk of kidney failure [<a href="#rid26">26</a>]. It is thought that nephrocalcinosis can cause kidney parenchymal inflammation and fibrosis and, if persistent, ESKD [<a href="#rid14">14</a>]. Other urinary complications associated with kidney stones, such as infection and obstruction, also contribute to kidney damage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic oxalosis</strong> – As the glomerular filtration rate (GFR) falls below 30 to 40 mL/min per 1.73 m<sup>2</sup>, plasma oxalate levels increase because of reduced urinary oxalate excretion [<a href="#rid11">11</a>]. When plasma oxalate exceeds 30 micromol/L, which is the plasma supersaturation threshold for calcium oxalate, calcium oxalate is deposited into other tissues including the retina, myocardium, vessel walls, skin, bone, and the central nervous system, which leads to oxalosis with the non-kidney manifestations of PH. (See <a class="local">'Systemic oxalosis'</a> below.)</p><p></p><p class="headingAnchor" id="H2905013423"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary hyperoxaluria (PH) is a rare disorder. PH type 1, which accounts for approximately 80 percent of cases, has an estimated prevalence of between one to three per million in Europe and North America [<a href="#rid27">27-29</a>]. However, this estimation does not account for potential underreporting, especially for the less severe types 2 and 3, and may change with the increasing availability of molecular testing [<a href="#rid14">14</a>].</p><p>Carrier frequency, based on the known pathologic alleles, was estimated at 1 in 58,000 in a study of genetic testing in 355 patients from the Rare Kidney Stone Consortium PH registry population, using data from the National Heart, Lung, and Blood Institute Exome Sequencing Project [<a href="#rid4">4</a>]. In this study, the prevalence of PH type 3 (the least severe type) was predicted to be the same as PH type 1 and twice as common as PH type 2. Population carrier rate was calculated to be lower in Black Americans than White Americans (ie, European ancestry).</p><p>In North America, PH type 1 is responsible for approximately 0.1 percent of cases of chronic kidney disease in children and is the primary diagnosis in 0.5 percent of children who undergo kidney transplantation [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL AND LABORATORY MANIFESTATIONS</span></p><p class="headingAnchor" id="H2111703101"><span class="h2">Primary hyperoxaluria type 1</span><span class="headingEndMark"> — </span>Primary hyperoxaluria (PH) type 1 is the most severe form of PH as these patients are more likely to progress to end-stage kidney disease (ESKD) and do so at an earlier age [<a href="#rid3">3,4,21,22</a>].</p><p class="headingAnchor" id="H3064121572"><span class="h3">Age of presentation</span><span class="headingEndMark"> — </span>The age at presentation is variable because of marked heterogeneity of disease expression. The median age at diagnosis is approximately 5 to 5.5 years of age but ranges from less than one year of age to over 50 years of age [<a href="#rid4">4,31,32</a>].</p><p class="headingAnchor" id="H16756187"><span class="h3">Kidney manifestations</span><span class="headingEndMark"> — </span>Five clinical presentations of PH type 1 have been described based on the age of presentation and kidney manifestations [<a href="#rid21">21,33,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infant with oxalosis (26 percent) – Infants generally present before six months of age with nephrocalcinosis and kidney impairment [<a href="#rid21">21,35,36</a>]. In a case series of 78 infants, presenting symptoms and findings included nephrocalcinosis (91 percent), failure to thrive (22 percent), urinary tract infection (21 percent), and ESKD (14 percent) [<a href="#rid36">36</a>]. ESKD developed at a mean age of three years and, in many cases, was present at the time of diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Child with recurrent kidney stones and rapid decline in kidney function (30 percent) – In these patients, the first symptoms are those usually associated with kidney stones (renal colic, hematuria, and urinary tract infection) and, occasionally, bilateral obstruction with acute kidney failure [<a href="#rid2">2,21,37</a>]. The calcium oxalate stones formed in patients with PH are bilateral and radiopaque on radiologic examination and are often seen in association of diffuse nephrocalcinosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult with occasional stone formation (30 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent disease after kidney transplantation (10 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family screening (approximately 10 to 15 percent) – Compared with patients diagnosed because of clinical suspicion, those identified after family screening were younger and had fewer number of stones at the time of diagnosis [<a href="#rid3">3,21</a>]. However, decline in kidney function and risk of developing ESKD were similar in both groups [<a href="#rid3">3</a>].</p><p></p><p>Early diagnosis is critical so that intensive medical therapy can be initiated that will delay the progression of ESKD. However, late detection is common and results in a significant number of patients who have ESKD at the time of diagnosis [<a href="#rid2">2,38</a>]. (See <a class="local">'Medical management'</a> below.)</p><p>ESKD develops in approximately one-half of patients by young adulthood without early diagnosis and medical intervention [<a href="#rid3">3,21,22,36</a>]. The rapidity of ESKD progression is variable and is dependent on residual enzyme activity and the response to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H82373131"><span class="h3">Systemic oxalosis</span><span class="headingEndMark"> — </span>When the glomerular filtration rate (GFR) falls below 30 to 40 mL/min per 1.73 m<sup>2</sup>, the combination of oxalate overproduction and reduced urinary oxalate excretion results in systemic oxalosis with potential calcium oxalate deposition in the heart, blood vessels, joints, bones, and retinas [<a href="#rid14">14,40-42</a>]. (See <a class="local">'Effects of oxalate deposition'</a> above.)</p><p>Deposition in these organs can lead to the following clinical manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – Cardiac conduction defects that may result in cardiac arrest [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Circulation</strong> – Poor peripheral circulation that results in distal gangrene and difficulties with vascular access for hemodialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone and joints</strong> – Bone manifestations that include pain, erythropoietin-resistant anemia, and an increased risk of spontaneous fracture [<a href="#rid34">34,44</a>]. Oxalate deposition may be seen as dense suprametaphyseal bands on x-rays and are most prominent in the metaphyses of long bones and trabecular bones. Osteoarticular manifestations are severe in patients who have been on dialysis for more than one year.</p><p></p><p class="bulletIndent1">Oxalate deposition in the joints can lead to synovitis with reduced mobility and pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vision</strong> – Oxalate deposition in the retinal epithelium and the macula can cause diminished visual acuity [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow</strong> – Oxalate deposition in the bone marrow leading to pancytopenia [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong> include hypothyroidism [<a href="#rid47">47</a>], peripheral neuropathy, dental problems (tooth pain, root resorption, and pulp exposure), and skin manifestations including livedo reticularis, peripheral gangrene, and metastatic calcinosis cutis [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">"Calcinosis cutis: Etiology and patient evaluation", section on 'Metastatic calcinosis cutis'</a>.)</p><p></p><p class="headingAnchor" id="H2160348220"><span class="h2">Primary hyperoxaluria type 2</span><span class="headingEndMark"> — </span>PH type 2 is generally a milder disease than PH type 1 as the risk for ESKD is lower and kidney function deterioration is slower [<a href="#rid2">2,4,50-52</a>].</p><p>Information on clinical findings is limited due to the rarity of the disease and is based on data from observational case series. The following clinical manifestations are based on findings from two large case series [<a href="#rid4">4,50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age at presentation and diagnosis</strong> – The reported median ages of first-noted symptom vary from 3.2 to 7.4 years. However, the age of presentation ranges from 0.1 to 41 years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney stones – The most common presentation is due to symptoms related to kidney stones, which include gross hematuria, renal colic, urinary tract infection, and, infrequently, urinary obstruction [<a href="#rid50">50,51</a>]. Kidney stones and nephrocalcinosis occur in more than 80 percent of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney function impairment and ESKD – Approximately one-quarter to one-third of patients with PH type 2 will progress to ESKD. The median age for reaching ESKD was 40 years (range 34 to 48 years of age), which is older than what is typical for PH type 1 disease.</p><p></p><p class="bulletIndent2">Approximately one-third of patients maintained normal kidney function and the remainder had evidence of kidney dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic oxalosis</strong> – Patients who progress to ESKD were also at risk for systemic oxalosis (eg, retinal deposits, cardiomyopathy, and conduction abnormalities).</p><p></p><p class="headingAnchor" id="H3326376238"><span class="h2">Primary hyperoxaluria type 3</span><span class="headingEndMark"> — </span>Data on the clinical manifestations and course of PH type 3 are more limited because the genetic basis for the disorder was first described in 2010. Patients with PH type 3 typically present early in life (mean age two years) with symptoms due to recurrent kidney stones (eg, hematuria, pain, and/or urinary tract infection) [<a href="#rid53">53</a>]. Although it was thought that after six years of age, recurrence of kidney stones was unlikely, data from the Rare Kidney Stone Consortium Primary Hyperoxaluria Registry indicated that the risk of recurrent stone disease was similar for patients with type 3 disease compared with those with types 1 and 2, and the risk continues through adulthood [<a href="#rid53">53</a>]. However, patients with type 3 disease have milder kidney disease than either type 1 or 2 and typically do not progress to ESKD [<a href="#rid4">4,19,53-55</a>]. In one study that included 38 patients with type 3 disease, one patient did progress to ESKD but kidney injury may have been aggravated by recurrent surgical procedures to remove kidney stones [<a href="#rid4">4</a>]. Patients may develop mild kidney function impairment [<a href="#rid53">53,56</a>].</p><p>Hyperoxaluria is often associated with hypercalcuria [<a href="#rid57">57</a>]. Increased urinary excretion of hydroxy-oxo-glutarate can be used for diagnosis [<a href="#rid53">53,58,59</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3917960225"><span class="h2">Step-wise diagnostic assessment</span><span class="headingEndMark"> — </span>The diagnosis of primary hyperoxaluria (PH) is made in a stepwise fashion based on:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical suspicion due to the presence of clinical manifestations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic testing demonstrating elevated urinary oxalate excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation by genetic testing demonstrating a variant of any of three known causative genes (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604296&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqP9U0smJv72BxGsqK1Z2uj&amp;TOPIC_ID=6141" target="_blank"><i>GRHPR</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613597&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz69AA%2BsAln8FLKazgoimJem&amp;TOPIC_ID=6141" target="_blank"><i>HOGA1</i></a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If no variant has been found, the diagnosis of PH type 1 and 2 can be made by a liver biopsy demonstrating absent or significantly reduced AGT or <em>GRHPR</em> activity [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H3037923944"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>Because of the rarity of PH, a strong clinical suspicion is needed to ensure there is not a delay in diagnosis, as the efficacy of treatment is dependent on early diagnosis. The diagnosis of PH should be suspected in children and infants with any of the following findings [<a href="#rid31">31,40,61,62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent calcium kidney stones  (<a class="graphic graphic_diagnosticimage graphicRef50463" href="/z/d/graphic/50463.html" rel="external">image 1</a>), especially in a patient with oxalate crystals in the urine sediment  (<a class="graphic graphic_picture graphicRef65169" href="/z/d/graphic/65169.html" rel="external">picture 1</a>) and normal urinary calcium and uric acid excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pure calcium oxalate monohydrate kidney stones (also referred to as whewellite)  (<a class="graphic graphic_picture graphicRef67694" href="/z/d/graphic/67694.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrocalcinosis, especially if associated with a decrease in glomerular filtration rate (GFR).</p><p></p><p class="headingAnchor" id="H2246449327"><span class="h2">Referral</span><span class="headingEndMark"> — </span>All patients with a confirmed diagnosis of PH should be under the care of a nephrologist. Patients should be referred to a nephrologist as soon as a diagnosis of PH is suspected. As a first step toward diagnosis, a primary care clinician can obtain urinary oxalate levels if the test is available.</p><p class="headingAnchor" id="H82374149"><span class="h2">Metabolic testing</span></p><p class="headingAnchor" id="H2460283512"><span class="h3">Increased urinary oxalate excretion</span><span class="headingEndMark"> — </span>A clinical diagnosis relies on metabolic screening that demonstrates a markedly <strong>increased</strong> urinary excretion of oxalate (ie, greater than 1 mmol/1.73 m<sup>2</sup> per day [90 mg/1.73 m<sup>2</sup> per day]) [<a href="#rid4">4</a>]. Patients with type 1 and 2 disease have higher urinary excretion of oxalate with levels as high as 1.5 to 3 mmol/1.73 m<sup>2</sup> per day (135 to 270 mg/1.73 m<sup>2</sup> per day). Normal urinary oxalate excretion is less than 0.5 mmol/1.73 m<sup>2</sup> per day (45 mg/1.73 m<sup>2 </sup>per day) [<a href="#rid63">63</a>]. Plasma oxalate concentration remains normal as long as the GFR is higher than 40 mL/min per 1.73 m<sup>2</sup> [<a href="#rid62">62</a>].</p><p>In some patients, obtaining a 24-hour urine collection is difficult, especially in infants and small children who are not toilet trained. As a result, oxalate excretion can be evaluated by measuring the molar oxalate:creatinine ratio in spot urine samples. Although <strong>normative</strong> values for oxalate:creatinine (mmol/mmol) vary by age and the assay method [<a href="#rid64">64-67</a>], the generally acceptable normal values based on age used to screen for hyperoxaluria are [<a href="#rid14">14,48,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infants less than 6 months of age – &lt;0.32 to 0.36</p><p class="bulletIndent1"><span class="glyph">●</span>Children between 6 months and 2 years of age – &lt;0.13 to 0.17</p><p class="bulletIndent1"><span class="glyph">●</span>Children between 2 and 5 years of age – &lt;0.098 to 0.1</p><p class="bulletIndent1"><span class="glyph">●</span>Children between 6 and 12 years of age – &lt;0.O7 to 0.08</p><p class="bulletIndent1"><span class="glyph">●</span>Patients &gt;16 years – &lt;0.04</p><p></p><p class="headingAnchor" id="H3577145759"><span class="h3">Plasma oxalate levels</span><span class="headingEndMark"> — </span>Urinary oxalate measurements may be falsely low in patients with kidney insufficiency and progressive disease, which is common in patients with type 1 disease. In this setting, plasma oxalate levels may be useful, as there is an inverse relation between plasma oxalate and kidney function in children with early stages of chronic kidney disease [<a href="#rid68">68</a>]. For these patients with reduced kidney function, increased plasma oxalate and glycolate concentrations can be used to help support the diagnosis of PH [<a href="#rid68">68-70</a>]. However, others have reported that plasma oxalate may not be a valid endpoint for clinical studies in PH 1 patients with normal or stable kidney function [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H2667808272"><span class="h3">Differentiating between the primary hyperoxaluria types</span><span class="headingEndMark"> — </span>Since all three types of PH have elevated urinary oxalate excretion, they can be distinguished from one another by assessing urinary excretion of metabolites associated with a specific underlying genetic cause of PH.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycolate and PH type 1</strong> – In general, hyperoxaluria plus increased urinary excretion of glycolate is strongly suggestive, but not absolutely diagnostic, of PH type 1 (normal urinary glycolate excretion is 0.5 mmol/1.73 m<sup>2</sup> per day [45 mg/1.73 m<sup>2</sup> per day]) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">For spot urine samples, the following are values of the molar glycolate:creatinine ratio based on age [<a href="#rid63">63</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants less than 6 months of age – &lt;0.36 to 0.42</p><p class="bulletIndent2"><span class="glyph">•</span>Children between 6 months and 2 years of age – &lt;0.24 to 0.29</p><p class="bulletIndent2"><span class="glyph">•</span>Children between 2 and 5 years of age – &lt;0.19 to 0.22</p><p class="bulletIndent2"><span class="glyph">•</span>Children between 6 and 12 years of age – &lt;0.16 to 0.18</p><p class="bulletIndent2"><span class="glyph">•</span>Patients &gt;16 years – &gt;0.09 to 0.12</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L-glyceric acid and PH type 2</strong> – Patients with type 2 PH typically have elevated levels of L-glyceric acid (&gt;28 mmol/mol creatinine), which is not observed in patients with type 1 or type 3 disease [<a href="#rid4">4,72</a>]. (See <a class="local">'Primary hyperoxaluria type 2'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxy-oxo-glutarate and PH type 3</strong> – Increased urinary excretion of hydroxy-oxo-glutarate can be used to diagnose PH type 3 [<a href="#rid53">53,58,59</a>].</p><p></p><p class="headingAnchor" id="H82374407"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Definitive diagnosis is possible by molecular testing for variants in any of the three known causative genes for PH (<em>AGXT</em>, <em>GRHPR</em>, and <em>HOGA1</em>). Genetic testing options include the following [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whole-gene sequencing</strong> should be performed if there is a high clinical index of suspicion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Next-generation sequencing</strong> has comparable diagnostic performance with manual or automated first-generation sequencing for the diagnosis of PH and screens for all forms of PH simultaneously, ensuring prompt diagnosis and decreased cost [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Terminology and evolution of technologies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted mutation analysis</strong> screens for the most common variants:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For PH type 1 – The detection rate is dependent on the number of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a><em> </em>variants used in the screening panel but generally ranges from 50 to 70 percent. In one study, the most common mutation (p.Gly170Arg) was found in 37 percent of alleles followed by a frame shift mutation (c.33_34insC) in 11 percent [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For PH type 2 – Analysis is targeted to detect the two most common variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604296&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqP9U0smJv72BxGsqK1Z2uj&amp;TOPIC_ID=6141" target="_blank"><i>GRHPR</i></a>, c.103delG (40 percent) in exon 2 and c.403_405+2 del AAGT (16 percent) in exon 4 [<a href="#rid75">75</a>].</p><p></p><p>A list of available laboratories for genetic testing can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fall%2Flabs%2F%3Fterm%3Dprimary%2Bhyperoxaluria&amp;token=PfHdKFgA58frHOA49zE2JsQFLyoV25CF%2FthLiVacJl9gDcUfM%2Fe%2FWwKF6V%2F6kRyZeMiIXrXrOiBpPSFit89NATJKTZKxSeOHmrpL0ih%2BFCk%3D&amp;TOPIC_ID=6141" target="_blank">National Institutes of Health Genetic testing registry</a> website.</p><p class="headingAnchor" id="H101664099"><span class="h3">Prenatal diagnosis</span><span class="headingEndMark"> — </span>Deoxyribonucleic acid (DNA) obtained from chorionic villi or amniotic cells is analyzed for the identified mutations found in the family, allowing detection of affected fetuses.</p><p class="headingAnchor" id="H101664106"><span class="h2">Liver biopsy</span><span class="headingEndMark"> — </span>Prior to the availability of genetic testing, the diagnosis of PH type 1 and 2 were confirmed by liver biopsy that demonstrated AGT deficiency for patients with PH type 1 disease and decreased <em>GRHPR</em> activity for those with type 2 disease. Evaluation of the hepatic tissue includes quantification of enzymatic activity, an immunoblot to analyze the protein, and an immunoelectronic examination of these enzymes [<a href="#rid76">76</a>].</p><p>If genetic testing is not available or a gene mutation has not been identified in a patient in whom there is a strong clinical suspicion for PH, liver biopsy to confirm the diagnosis is required prior to liver transplantation.</p><p class="headingAnchor" id="H4112450272"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of primary hyperoxaluria (PH) includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary hyperoxaluria – Ongoing excessive oxalate intake due to consumption with foods rich in oxalate such as chocolate, cocoa, leafy green vegetables (eg, rhubarb and spinach), black teas, nuts, peanut butter, and starfish fruit [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enteric hyperoxaluria – Increased intestinal oxalate absorption associated with fat malabsorption due to malabsorptive bariatric surgery, small bowel disease, or cystic fibrosis [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/6112.html" rel="external">"Kidney stones in children: Epidemiology and risk factors", section on 'Hyperoxaluria'</a> and  <a class="medical medical_review" href="/z/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children", section on 'Hyperoxaluria and kidney stones'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combinations of etiologies – Absence of intestinal oxalate degrading bacteria (<em>Oxalobacter</em> <em>formigenes</em>) and relatively high oxalate diets or small bowel disease and cystic fibrosis.</p><p></p><p>Metabolic screening differentiates the disorders above from PH. Although elevated urinary oxalate excretion can be seen in patients with excess intake of oxalate (dietary hyperoxaluria), or in patients with increased intestinal oxalate absorption due to small bowel diseases (enteric hyperoxaluria), these levels are usually typically below 1 mmol/day (90 mg/day), which are below the levels seen in patients with PH [<a href="#rid61">61</a>]. In addition, genetic confirmation of PH excludes these disorders. (See <a class="local">'Increased urinary oxalate excretion'</a> above.)</p><p class="headingAnchor" id="H101664585"><span class="h1">EVALUATION AFTER DIAGNOSIS</span><span class="headingEndMark"> — </span>Once the diagnosis of primary hyperoxaluria (PH) has been confirmed, additional evaluation assesses the function of potentially affected organs [<a href="#rid48">48,62</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney function is evaluated by obtaining serum creatinine levels as a measure of glomerular filtration rate (GFR). (See  <a class="medical medical_review" href="/z/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation", section on 'Serum creatinine and glomerular filtration rate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone radiographs to detect radiodense metaphyseal bands and diffuse demineralization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid function tests to detect thyroid dysfunction. (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram to detect abnormalities in cardiac conduction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin measurement to detect anemia due to chronic kidney disease or as a result of oxalate deposition in bone marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with systemic oxalosis, further evaluation to determine the extent of end-organ involvement should include eye evaluation (including slit lamp examination), bone density determination, electrocardiography, and echocardiography.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1435551754"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Information on the management of primary hyperoxaluria (PH) is primarily derived from treating patients with PH type 1, the most common form of the disease. The efficacy of treatment in PH type 1 is dependent on early diagnosis. In particular, for patients with PH type 1, the initiation of medical management (reduction of urinary calcium oxalate excretion) as soon as possible prolongs kidney function, which delays end-stage kidney disease (ESKD) and potentially minimizes non-kidney sequelae. (See <a class="local">'Medical management'</a> below.)</p><p>Through 2021, our clinical practice for individuals with ESKD due to PH has been combined liver and kidney transplantation. Liver transplantation provides the definitive cure for PH type 1 by restoring the missing enzyme, which lowers oxalate production to the normal range. However, with the introduction of new ribonucleic acid interference (RNAi) drugs, it is unclear whether liver transplantation will be necessary in the future. The hope is that these new interventions will significantly alter oxalate production, thereby slowing the progression of kidney injury and the risk of ESKD [<a href="#rid7">7,78,79</a>]. (See <a class="local">'Transplantation'</a> below.)</p><p class="headingAnchor" id="H58187731"><span class="h2">Medical management</span><span class="headingEndMark"> — </span>Medical management is focused on reduction of urinary calcium oxalate saturation and oxalate production, thereby minimizing kidney oxalate deposition and delaying the progression of kidney injury [<a href="#rid62">62,80</a>]. (See <a class="local">'Effects of oxalate deposition'</a> above.)</p><p class="headingAnchor" id="H3576383165"><span class="h3">General measures in all patients</span><span class="headingEndMark"> — </span>Management for all forms of PH includes the following modalities, all of which may be started simultaneously [<a href="#rid40">40,61,62,81,82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased fluid intake</strong> – Large fluid intake resulting in a high urinary output (greater than 3 L/day per 1.73 m<sup>2</sup>) is the most effective therapy to decrease tubular fluid oxalate concentration and diminish intratubular oxalate deposition. A gastric tube or a percutaneous gastrostomy may be necessary in young children to maintain this high urine flow around the clock.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibition of calcium oxalate precipitation</strong> – Alkalinization of urine with <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">potassium citrate</a> can reduce urinary calcium oxalate saturation by forming complexes with calcium, which decreases stone formation. We use oral potassium citrate at a dose of 0.15 g/kg divided into two or three doses per day. If kidney function is impaired and plasma potassium is increased, sodium citrate can replace potassium citrate.</p><p></p><p class="bulletIndent1">Other inhibitors of calcium oxalate crystallization, which are used selectively, include neutral phosphate (20 to 30 mg/kg) or <a class="drug drug_general" data-topicid="9583" href="/z/d/drug information/9583.html" rel="external">magnesium oxide</a> (500 mg/day per m<sup>2</sup>), also given orally, divided into two or three doses per day. Phosphate supplements should be discontinued in patients with impaired kidney function who develop hyperphosphatemia. If a patient's glomerular filtration rate (GFR) decreases, a serum phosphate level should be obtained. If hyperphosphatemia is present, phosphate supplementation should be stopped in order to prevent phosphate accumulation and exacerbation of secondary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a> and  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones", section on 'Hyperoxaluria and oxalosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary oxalate restriction</strong> – Although intestinal oxalate absorption is lower in patients with PH compared with healthy subjects, foods with high oxalate content (such as tea, chocolate, spinach, and rhubarb) should be restricted from their diet [<a href="#rid83">83</a>]. However, as most of the oxalate is of an endogenous source, these dietary measures are of minor impact in most patients.</p><p></p><p class="headingAnchor" id="H2964997005"><span class="h3">Additional therapies for primary hyperoxaluria type 1</span><span class="headingEndMark"> — </span>For PH type 1, we suggest a trial of pyridoxal phosphate and recommend ongoing treatment with the RNAi agents <a class="drug drug_general" data-topicid="130214" href="/z/d/drug information/130214.html" rel="external">lumasiran</a> or <a class="drug drug_general" data-topicid="142919" href="/z/d/drug information/142919.html" rel="external">nedosiran</a>. <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Pyridoxine</a> supplements may be used simultaneously with lumasiran or nedosiran.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Pyridoxine</a><strong> supplementation</strong> – For all patients with type 1 PH, we suggest a three to six month trial of high-dose pyridoxine (pyridoxal phosphate) based upon case series reporting that the combination of pyridoxine and a neutral phosphate started at an early age slows the progression to ESKD [<a href="#rid81">81,84</a>]. We begin pyridoxine therapy at a dose of 5 mg/kg divided into one or two doses per day. We then assess the response to therapy by comparing the 24-hour urine oxalate excretion before and after treatment. A positive response is defined as a reduction in urinary oxalate of greater than 30 percent. In patients who are responsive, we continue pyridoxine indefinitely or until liver transplantation is performed. If the patient has not had a positive response to pyridoxine after four to six weeks, the dose can be titrated up to a maximum of 20 mg/kg per day. The medication is discontinued if there is no significant decrease in urinary oxalate excretion. Large doses of pyridoxine may induce sensory neuropathy [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Pyridoxine</a> is a coenzyme of alanine-glyoxylate aminotransferase (AGT) that promotes the conversion of glyoxylate to glycine, rather than to oxalate. Approximately 10 to 30 percent of patients with PH type 1 will respond to pyridoxine therapy with a significant reduction of urinary oxalate excretion, particularly those patients with homozygous <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a> p.Gly170Arg or p.Phe152Ile mutations [<a href="#rid14">14,23,81,86-90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumasiran</strong> – <a class="drug drug_general" data-topicid="130214" href="/z/d/drug information/130214.html" rel="external">Lumasiran</a> is an RNAi therapeutic agent that targets glycolate oxidase resulting in depletion of the substrate for oxalate synthesis, thereby reducing oxalate production [<a href="#rid91">91-93</a>]. Our practice is to start lumasiran as a first-line treatment in patients with confirmed PH type I. Lumasiran is administered subcutaneously and dosing is weight-based:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients &lt;10 kg, the initial dose is 6 mg/kg monthly for three months, followed by 3 mg/kg monthly</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients 10 to 20 kg, the initial dose is 6 mg/kg monthly for three months, followed by 6 mg/kg every three months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients &gt;20 kg, the initial dose is 3 mg/kg monthly for three months, followed by 3 mg/kg every three months</p><p></p><p class="bulletIndent1">The US Food and Drug Administration approved <a class="drug drug_general" data-topicid="130214" href="/z/d/drug information/130214.html" rel="external">lumasiran</a> as initial therapy for PH type 1 in 2020 [<a href="#rid94">94,95</a>]. The approval was based on two clinical studies in patients, including children &lt;6 years of age, which reported that lumasiran decreased urinary oxalate excretion by &gt;50 percent and normalized urinary oxalate excretion in approximately one-half of participants, and had no significant adverse effects, with subsequent confirmatory studies [<a href="#rid78">78,96,97</a>]. In a series of 18 infants and children &lt;6 years with PH type 1, lumasiran reduced spot oxalate:creatinine ratio by 72 percent at 6 and 12 months [<a href="#rid98">98</a>]. In patients with PH type 1 with advanced kidney disease, lumasiran results in substantial reductions in plasma oxalate, with an acceptable safety profile [<a href="#rid99">99</a>]. Long-term follow-up is needed to assess the efficacy of lumasiran in reducing the risk of ESKD, reducing stone formation, and stabilizing kidney function. The annual cost of this medication is estimated at USD $379,100 [<a href="#rid94">94</a>], which will impact its clinical accessibility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nedosiran</strong> – <a class="drug drug_general" data-topicid="142919" href="/z/d/drug information/142919.html" rel="external">Nedosiran</a> is a second-generation RNAi therapeutic agent that targets the messenger RNA (mRNA) encoding hepatic lactate dehydrogenase A. In a randomized trial in individuals with PH type 1 or 2 (n = 35, age 9 to 46 years, 29 with PH type 1), nedosiran significantly decreased urinary oxalate excretion and approximately one-half of participants achieved sustained normal or near-normal excretion levels between 90 and 180 days of treatment [<a href="#rid100">100</a>], which was sustained in a six-month open-label extension [<a href="#rid101">101</a>]. Nedosiran efficacy in this trial was driven by substantial lowering of urinary oxalate excretion in participants with PH type 1, with mean 24-hour urinary oxalate excretion sustained in the normal or near-normal range in this subgroup. In contrast, there was no consistent pattern of change in 24-hour urinary oxalate excretion in the subgroup with PH type 2. This small trial did not detect safety concerns other than injection-site reactions. The trial was the basis for approval of nedosiran for treatment of PH type 1 by the US Food and Drug Administration in October 2023 [<a href="#rid101">101</a>].</p><p></p><p class="headingAnchor" id="H4137433270"><span class="h3">Investigational agents</span><span class="headingEndMark"> — </span>The following agents are in development and are not routinely used in clinical practice.</p><p class="bulletIndent1"><span class="glyph">●</span><em>O</em>. <em>formigenes</em> – Enhancing oxalate elimination by the gastrointestinal tract is another potential method to reduce tissue and body oxalate levels. One proposed mechanism is the administration of <em>O</em>. <em>formigenes</em>, an obligate anaerobic colonic bacterium that promotes endogenous oxalate intestinal excretion [<a href="#rid102">102,103</a>]. We do <strong>not</strong> routinely administer <em>O</em>. <em>formigenes</em> therapy, as evidence regarding its use in patients with PH is inconclusive. Results from clinical trials are inconsistent on whether urinary oxalate is reduced in patients who received oral <em>O</em>. <em>formigenes</em> therapy compared with those given placebo [<a href="#rid104">104-107</a>]; similar numbers of serious adverse effects were reported. Further study is needed to determine whether <em>O</em>. <em>formigenes</em> therapy effectively and safely prevents or slows the progression of ESKD in patients with PH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>O</em>. <em>formigenes</em>-derived bioactive factors – Although the administration of <em>O</em>. <em>formigenes</em> has not been shown to improve outcome, data from in vitro human cell cultures and a mouse model using <em>O</em>. <em>formigenes</em> culture-conditioned medium have suggested a potential role for <em>O</em>. <em>formigenes</em>-derived bioactive factors as a novel therapeutic agent for prevention and/or treatment of hyperoxaluria [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dequalinium – <a class="drug drug_general" data-topicid="139621" href="/z/d/drug information/139621.html" rel="external">Dequalinium</a> chloride may be beneficial as it may restore normal peroxisomal trafficking of AGT, thereby inhibiting the misdirected AGT transport into the mitochondria [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stiripentol – <a class="drug drug_general" data-topicid="93717" href="/z/d/drug information/93717.html" rel="external">Stiripentol</a> is an antiseizure medication that decreases hepatic oxalate production, is a potentially promising agent. Stiripentol reduced urinary oxalate excretion and kidney oxalate deposition in rat model studies and decreased urinary oxalate excretion in a 17-year-old patient with severe type 1 hyperoxaluria [<a href="#rid110">110</a>]. However, another case report suggested that stiripentol was not clinically effective in two patients with PH type 1 [<a href="#rid111">111</a>]. A phase 2 clinical trial (NCT03819647) is planned to study the effects of this drug in reducing urinary oxalate excretion in patients with hyperoxaluria [<a href="#rid112">112</a>].</p><p></p><p class="headingAnchor" id="H2969466640"><span class="h3">Monitoring response to therapy</span><span class="headingEndMark"> — </span>In a stable patient, response to therapy should be assessed with a 24-hour urinary oxalate excretion test every three months. Urinary oxalate concentration should be maintained below 0.5 mmol/1.73 m<sup>2</sup> body surface area per day [<a href="#rid63">63</a>]. If a patient is unstable, this test may be performed more often. Other tests performed (eg, serum creatinine, kidney ultrasound) depend on the response to therapy demonstrated by the urinary oxalate excretion.</p><p class="headingAnchor" id="H22970959"><span class="h2">Management of kidney stones</span><span class="headingEndMark"> — </span>Intervention is required when stones obstruct the urinary tract. Nephrostomy, ureteroscopy, and ureteral JJ stent are preferred interventions for stone removal. Open surgical removal may precipitate acute kidney failure and extracorporeal shock-wave lithotripsy may harm the kidney because of the potential presence of nephrocalcinosis and microlithiasis within the kidney [<a href="#rid113">113-115</a>]. However, repeated surgical interventions may also contribute to kidney injury and ESKD [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/6114.html" rel="external">"Kidney stones in children: Acute management", section on 'Urologic intervention'</a>.)</p><p class="headingAnchor" id="H22970966"><span class="h2">Dialysis</span><span class="headingEndMark"> — </span>Intensive dialysis (eg, five-hour daily hemodialysis [HD] sessions, nocturnal HD, or a combination of HD and peritoneal dialysis [PD]) is needed to try to match daily oxalate production, but, in many PH patients, even intensive dialysis therapy remains inadequate to keep up with their daily oxalate production [<a href="#rid117">117</a>]. The maximal oxalate elimination via conventional HD and PD is 950 to 1440 micromol/day, which is significantly lower than the daily oxalate production of 3500 to 7500 micromol in patients with PH type 1 [<a href="#rid118">118,119</a>]. Predialysis plasma oxalate ranges between 100 and 200 micromol/L with a 60 to 80 percent reduction after hemodialysis. However, plasma oxalate returns to 80 percent of the predialysis value within 24 hours and 95 percent 48 hours after dialysis [<a href="#rid120">120</a>]. As a consequence, despite standard maintenance dialysis therapy, plasma oxalate typically exceeds the supersaturation threshold of 30 micromol/L during a substantial amount of time between dialysis treatments, thereby increasing the risk and progression of systemic oxalosis. (See <a class="local">'Systemic oxalosis'</a> above and <a class="local">'Effects of oxalate deposition'</a> above.)</p><p>Intensive dialysis therapy may be useful prior to kidney transplantation to decrease plasma oxalate as much as possible to reduce subsequent oxalate deposition and injury in the kidney allograft. (See <a class="local">'Isolated kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H58182972"><span class="h2">Transplantation</span></p><p class="headingAnchor" id="H80423130"><span class="h3">Choice of transplant option</span><span class="headingEndMark"> — </span>The optimal transplantation strategy for patients with PH of all types remains uncertain [<a href="#rid121">121</a>]. Regardless of the chosen procedure, the surgery should be performed at a center with expertise in transplantation and the care of patients with PH. There are four possible transplantation options:</p><p class="bulletIndent1"><span class="glyph">●</span>Combined liver and kidney transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Sequential liver and kidney transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated liver transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated kidney transplantation</p><p></p><p>Liver transplantation is the only curative intervention for PH type 1 because it corrects the underlying enzymatic defect due to mutations of the <em>AGXT</em> gene. Preemptive liver transplant in patients with GFRs greater than 40 mL/kg per 1.73 m<sup>2</sup> has been proposed as curative treatment. However, this presupposes progression of kidney disease despite aggressive medical management and exposes the patient to the known risk factors associated with liver transplantation and removal of a native liver that is normal except for the absence or reduction in AGT activity. Complications include those due to immunosuppressive therapy (eg, infections or adverse drug effects, such as calcineurin inhibitor-induced nephrotoxicity), secondary malignancy, and failure of the liver allograft. If preemptive liver transplantation is considered, the optimal timing is unknown, as there are no data that provide an accurate prediction of the clinical course in patients who are diagnosed prior to significant kidney damage and treated with aggressive medical management, especially patients who are responsive to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> therapy.</p><p>For patients with PH type 1 with significant chronic kidney disease, combined liver and kidney transplantation has been advocated over isolated kidney transplantation. This is because replacement of the native liver corrects the underlying metabolic defect and thus reduces the exposure of the kidney graft to the damaging effects of hyperoxaluria. However, even with combined liver and kidney transplantation, the new allograft is still exposed to some hyperoxaluria because tissue stores of oxalate are mobilized with the return of kidney function. After the transplant, urine oxalate can remain elevated for many months due to the slow resolubilization of systemic calcium oxalate. As long as urinary oxalate remains elevated, these patients should continue with a high fluid intake and treatment with crystallization inhibitors to protect the transplanted kidney from calcium oxalate damage. Long-term data comparing these approaches are insufficient to determine the optimal approach. As an example, death-censored kidney allograft survival is greater in recipients of combined liver and kidney transplants compared with recipients of isolated kidney transplants, but patient survival may be similar or even lower [<a href="#rid121">121-123</a>]. The duration of kidney allograft survival is also unknown in patients with isolated kidney transplantation who are treated with intensive medical therapy immediately after transplantation, especially in those who are responsive to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> therapy.</p><p>For patients with PH type 2 who progress to ESKD, data are insufficient to guide the optimal choice of transplantation. Although isolated kidney transplantation has been the recommended approach [<a href="#rid14">14,121,124</a>], immediate recurrence and subsequent graft loss were reported in a pediatric patient with PH type 2 who underwent isolated kidney transplantation [<a href="#rid125">125</a>]. Case reports of combined liver/kidney transplant in adults have shown normalization of plasma oxalate, urine oxalate, and urine glycerate levels, including in one adult patient who experienced a rapid and severe relapse of oxalate nephropathy after isolated kidney transplant [<a href="#rid126">126,127</a>]. Further information is required to determine whether liver transplantation is beneficial in patients with PH type 2 disease [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Combined liver and kidney transplantation</span><span class="headingEndMark"> — </span>Combined liver and kidney transplantation has become the treatment used in children with PH type 1 with progressive kidney disease [<a href="#rid35">35,121,128-131</a>]. The liver provides the missing enzyme, thereby lowering oxalate production to the normal range. This modality should be considered only after confirming that the diagnosis is PH type 1. The outcome of simultaneous transplantation is probably best when the procedure is performed when the GFR falls below 40 mL/min per 1.73 m<sup>2</sup> and prior to marked tissue oxalate deposition.</p><p>The following observational outcome data demonstrate that combined liver and kidney transplantation had a better graft survival compared with isolated kidney transplantation.</p><p class="bulletIndent1"><span class="glyph">●</span>The International Primary Hyperoxaluria Registry compared outcomes of different transplantation approaches for patients who were transplanted between 1976 and 2009 [<a href="#rid121">121</a>]. In this cohort, 32 patients received an isolated kidney graft, and 26 patients received a combined liver and kidney. Three patients with a combined liver and kidney transplantation died with functioning allografts, which resulted in a lower five-year patient survival (67 versus 100 percent). However, the three-year kidney graft survival for survivors was higher with combined grafts compared with isolated kidney graft (95 versus 56 percent). Of note, patients with isolated kidney transplants had a greater delay in diagnosis (including 11 patients who were undiagnosed at the time of transplantation) and were more likely to have their transplantation performed before 2000.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a European report of patients less than 19 years old, kidney survival at three months and five years was only 54 percent and 14 percent for isolated kidney transplantation, compared with 82 percent and 76 percent for combined liver and kidney transplantation, suggesting that isolated kidney transplantation is not a good option in children who have progressed to kidney failure [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term outcome of a consecutive French case series of 54 patients with transplants performed between 1979 and 2010 reported similar 10-year patient survival between liver and kidney transplantation (n = 33) and isolated kidney transplantation (n = 21) groups (78 versus 70 percent) [<a href="#rid130">130</a>]. Ten-year kidney graft survival was better after combined liver and kidney transplantation (87 versus 13 percent).</p><p></p><p>After combined transplantation, there is gradual mobilization of tissue oxalate deposits, and elevated urinary oxalate excretion may persist for as long as or even longer than two years as tissue stores are removed [<a href="#rid121">121</a>]. The same management strategies used for patients with isolated kidney transplant are employed in patients undergoing combined liver and kidney transplantation to decrease hyperoxaluria. This includes aggressive medical management (high fluid intake, and the administration of neutral phosphate, <a class="drug drug_general" data-topicid="10066" href="/z/d/drug information/10066.html" rel="external">potassium citrate-citric acid</a>, and/or <a class="drug drug_general" data-topicid="9583" href="/z/d/drug information/9583.html" rel="external">magnesium oxide</a>), and the administration of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> in responsive patients. The duration of medical intervention varies, depending on the amount of oxalate tissue stores. Medical management is discontinued when urine oxalate excretion returns to normal values. Bilateral native nephrectomy at the time of transplantation reduces oxalate stores [<a href="#rid132">132</a>]. (See <a class="local">'Medical management'</a> above and <a class="local">'Isolated kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H637663340"><span class="h3">Sequential liver and kidney transplantation</span><span class="headingEndMark"> — </span>Another option is sequential transplantation (first liver followed by kidney transplantation), which has been performed in children with PH type 1 and ESKD [<a href="#rid133">133-135</a>]. The rationale underlying this approach is the initial liver transplant allows intensive dialysis to clear the stores of tissue oxalates in patients who have been on dialysis for prolonged periods of time, thereby reducing the risk of kidney injury after kidney transplantation. In addition, sequential transplantation may be performed in small recipients in whom a combined simultaneous transplantation is not feasible, because of anatomical reasons or medical instability [<a href="#rid129">129,135,136</a>].</p><p>The medical management of patients after sequential transplantation is the same as that used for patients who undergo combined liver and kidney transplantation discussed above.</p><p class="headingAnchor" id="H58184340"><span class="h3">Isolated liver transplantation</span><span class="headingEndMark"> — </span>Isolated liver transplantation has been proposed for patients with progressive disease who still have a GFR between 40 to 60 mL/min per 1.73 m<sup>2</sup> [<a href="#rid134">134</a>]. In a case series of 18 individuals with a GFR &gt;50 mL/kg/1.73 m<sup>2</sup>, the seven individuals who underwent preemptive liver transplantation experienced preserved kidney function; median eGFR was 72 (range 50 to 89) mL/kg/1.73 m<sup>2</sup> at transplantation and 104 mL/kg/1.73 m<sup>2</sup> (range 86 to 108) at follow-up 6 to 27 years later [<a href="#rid137">137</a>]. By contrast, in a comparison group of 11 patients who were managed conservatively, eight reached stage 5 CKD and two died. Similar outcomes were seen in earlier case reports [<a href="#rid134">134,138-142</a>].</p><p>Liver transplantation requires native hepatectomy, even though the liver is normal in all other aspects, because any remaining defective hepatic cells will continue to produce large amounts of oxalate. The significant morbidity and mortality associated with liver transplantation has led to hesitation to adopt preemptive liver transplantation in the absence of significant kidney impairment [<a href="#rid122">122,143,144</a>]. Moreover, outcomes of conservative management have generally improved due to early diagnosis and initiation of intensive medical therapy, including <a class="drug drug_general" data-topicid="130214" href="/z/d/drug information/130214.html" rel="external">lumasiran</a> [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Isolated kidney transplantation</span><span class="headingEndMark"> — </span>Isolated kidney transplantation has generally been supplanted by combined liver and kidney transplantation [<a href="#rid121">121</a>] because the experience of kidney transplantation alone in PH had been relatively disappointing, as oxalate deposition from newly formed and mobilized tissue oxalate led to loss of the allograft in many patients.</p><p>Data from the European Dialysis and Transplant Association on 98 PH patients with first transplant prior to 1990 showed a three-year graft survival rate of only 23 percent for living related donor kidneys and 17 percent for cadaver kidneys [<a href="#rid145">145</a>]. In a study from the European Pediatric Nephrology Registry of 100 children who were less than 19 years and received an isolated kidney transplantation between 1979 and 2009, graft survival in those with PH was lower compared with that of children without PH at one year (46 versus 95 percent), three years (28 versus 90 percent), and five years (14 percent versus 85 percent) follow-up [<a href="#rid38">38</a>]. Similar dismal results were observed in a report of a single center's transplantation experience [<a href="#rid146">146</a>].</p><p>Isolated kidney transplantation may be an option in selected patients who are responsive to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a>, such as those with homozygous <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a> p.Gly170Arg or p.Phe152Ile mutations [<a href="#rid62">62,147,148</a>]. However, these patients should not progress to kidney failure if the diagnosis is made early and timely aggressive medical management including pyridoxine therapy is provided prior to extensive kidney injury. Isolated kidney transplantation may also be an option in adults with a late-onset form of the disease [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H722641921"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognosis is different for the different types of primary hyperoxaluria (PH).</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with type 1 PH have had the most dire prognosis, with end-stage kidney disease (ESKD) developing in approximately one-half of these patients by young adulthood without early diagnosis and treatment [<a href="#rid3">3,21,22,36</a>]. How quickly a patient with PH 1 progresses to ESKD is variable and is dependent on residual enzyme activity and response to treatment. RNA interference (RNAi) agents, such as <a class="drug drug_general" data-topicid="130214" href="/z/d/drug information/130214.html" rel="external">lumasiran</a>, appear to slow the progression of chronic kidney disease, including ESKD, which may have an impact on prognosis for patients with PH type 1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PH type 2 is generally a milder disease than PH type 1 as the risk for ESKD is lower and kidney function deterioration is slower [<a href="#rid2">2,4,50-52</a>]. Approximately one-quarter to one-third of patients with PH type 2 will progress to ESKD. Approximately one-third of patients with PH 2 maintain normal kidney function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with type 3 disease have milder kidney disease than either type 1 or 2. These patients typically develop mild kidney function impairment but do not progress to ESKD [<a href="#rid4">4,19,53-55</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">ADDITIONAL INFORMATION</span><span class="headingEndMark"> — </span>Additional information about primary hyperoxaluria can be obtained from the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient information:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Oxalosis and Hyperoxaluria Foundation</p><p class="bulletIndent2">201 East 19<sup>th</sup> Street, Suite 12E</p><p class="bulletIndent2">New York, NY 10003</p><p class="bulletIndent2">212-777-0470</p><p class="bulletIndent2"><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fohf.org%2F&amp;token=WxmQ23Pm9t8i6XiyNixiKqeQkCCwZKJSIuZpU2jJh0M%3D&amp;TOPIC_ID=6141" target="_blank">www.ohf.org</a></p><p class="bulletIndent2">Email – <a class="__cf_email__" data-cfemail="4d02050b0d02050b1821393f2c232839632e2220" href="/cdn-cgi/l/email-protection">[email protected]</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>OxalEurope</p><p class="bulletIndent2"><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.oxaleurope.org%2F&amp;token=HneFtAsfUPj3YgsYN2STEng1YVxmHMWzS3TCtWolIGQOoppajjY0XEKn6kMDjtER&amp;TOPIC_ID=6141" target="_blank">www.OxalEurope.org</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>University College London Hospitals clinical biochemistry service provides metabolic and genetic testing</p><p class="bulletIndent2"><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.uclh.nhs.uk%2Four-services%2Ffind-service%2Fpathology-1%2Fclinical-biochemistry&amp;token=xUfZ8q1MKhpsxK8Uudjtdfh%2B3AofZaepeZDCsXYFZbgMhs880qs3yZZu7wX0tr%2B%2BFjXZ0DRwQhDFPcTB7dbMqgdOcKcnOHizGNNAJ1Mhxmw%3D&amp;TOPIC_ID=6141" target="_blank">www.uclh.nhs.uk/our-services/find-service/pathology-1/clinical-biochemistry</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>National Institutes of Health Genetic testing registry lists laboratories that are available for genetic testing</p><p class="bulletIndent2"><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=6141" target="_blank">www.ncbi.nlm.nih.gov/gtr</a></p><p></p><p class="headingAnchor" id="H60192426"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Primary hyperoxaluria (PH) is a rare inborn error of glyoxylate metabolism characterized by the overproduction of oxalate, which is deposited as calcium oxalate in various organs. Deposition in the kidney may lead to end-stage kidney disease (ESKD) in some cases. (See <a class="local">'Introduction'</a> above and <a class="local">'Effects of oxalate deposition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – PH is primarily caused by autosomal recessive enzymatic defects in pathways of glyoxylate metabolism that result in enhanced oxalate production  (<a class="graphic graphic_figure graphicRef117739" href="/z/d/graphic/117739.html" rel="external">figure 1</a>). (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PH type 1</strong> (approximately 70 to 80 percent of cases based on clinical observational studies) is due to variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604285&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqcm3MbXCsQ1Z5QV9S6Ddil&amp;TOPIC_ID=6141" target="_blank"><i>AGXT</i></a> gene that encodes the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT). (See <a class="local">'Primary hyperoxaluria type 1'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PH type 2</strong> (10 percent of cases) is due to variants of glyoxylate reductase/hydroxypyruvate reductase that encodes the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604296&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqP9U0smJv72BxGsqK1Z2uj&amp;TOPIC_ID=6141" target="_blank"><i>GRHPR</i></a> gene.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PH type 3</strong> (5 percent of cases) is due to variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613597&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz69AA%2BsAln8FLKazgoimJem&amp;TOPIC_ID=6141" target="_blank"><i>HOGA1</i></a> gene that encodes the mitochondrial 4-hydroxy-2-oxoglutarate aldolase enzyme, which catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of end-organ damage</strong> – In patients with PH, increased urinary excretion of oxalate results in oversaturation of the urine with calcium oxalate, leading to kidney stones and nephrocalcinosis. Recurrent stones and progressive nephrocalcinosis cause kidney parenchymal inflammation and fibrosis, which, if persistent, may progress to ESKD. As kidney function deteriorates, plasma oxalate increases further, leading to calcium oxalate deposition into non-kidney tissues (systemic oxalosis), including the retina, myocardium, vessel walls, skin, bone, and central nervous system. (See <a class="local">'Effects of oxalate deposition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PH type 1</strong> – The presentation of PH type 1 varies depending on age and clinical findings because of marked heterogeneity of disease expression. Affected infants and children generally present at a median age of five years (range from &lt;1 year to over 50 years of age) with symptoms related to nephrocalcinosis, kidney stones, and/or chronic kidney disease. ESKD develops in approximately one-half of patients by young adulthood. As kidney function deteriorates, non-kidney manifestations due to systemic oxalosis develop and include cardiac conduction defects, bony pain and increased risk of fractures, and diminished visual acuity. (See <a class="local">'Primary hyperoxaluria type 1'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PH type 2</strong> – Patients with PH type 2 primarily present with recurrent kidney stones and may progress to ESKD, typically at an older age than patients with PH type 1 disease. Patients with progressive kidney dysfunction will also have evidence of systemic oxalosis. (See <a class="local">'Primary hyperoxaluria type 2'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PH type 3</strong> – Patients with PH type 3 generally present early in life (mean age two years) with kidney stones. In contrast with the other two forms of PH, patients with PH type 3 typically do not progress to ESKD. (See <a class="local">'Primary hyperoxaluria type 3'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and referral</strong> – The diagnosis of PH is based on recognition of clinical findings suggestive of PH (eg, recurrent kidney stones or nephrocalcinosis), a markedly increased urinary oxalate excretion, and confirmation by molecular genetic testing. In cases where genetic testing is negative, liver biopsy demonstrating decreased or absent activity of AGT for type 1 disease and <em>GRHPR</em> for type 2 is used to confirm the diagnosis. Metabolic testing is useful in differentiation amongst the three different types. Patients should be referred to a nephrologist as soon as a diagnosis of PH is suspected. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Referral'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential of PH includes secondary oxalosis due to increased oxalate intake or oxalate reabsorption due to small bowel disease. The different forms of PH are distinguished from these other conditions by higher urinary oxalate excretion rates and molecular testing. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Information on the management of PH is primarily derived from treating patients with PH type 1, the most common and severe form of the disease. The efficacy of treatment in PH type 1 is dependent on early diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medical interventions</strong> – The following medical interventions reduce calcium oxalate deposition and kidney impairment in patients with PH types 1 and 2. (See <a class="local">'Medical management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients for all forms of PH, high fluid intake (greater than 3 L/1.73 m<sup>2</sup> per day) is routinely provided to decrease tubular fluid oxalate concentration and diminish intratubular oxalate deposition. The goal is to maintain urinary oxalate concentration below 0.5 mmol/1.73 m<sup>2</sup> body surface area per day.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with PH types 1 and 2, we suggest the use of agents that increase the solubility of calcium oxalate (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use oral <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">potassium citrate</a> at a dose of 0.15 g/kg divided into two or three doses per day. Other agents include neutral phosphate (20 to 30 mg/kg) or <a class="drug drug_general" data-topicid="9583" href="/z/d/drug information/9583.html" rel="external">magnesium oxide</a> (500 mg/day per m<sup>2</sup>), also given orally and divided into two to three doses per day.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with PH type 1, we suggest a three-month trial of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In approximately 30 percent of patients with PH type 1, pyridoxine reduces urinary oxalate secretion. Pyridoxine is not effective in patients with PH type 2.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with PH type 1, we recommend RNA interference (RNAi) therapy, in addition to the general measures and <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> described above (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). <a class="drug drug_general" data-topicid="130214" href="/z/d/drug information/130214.html" rel="external">Lumasiran</a> or <a class="drug drug_general" data-topicid="142919" href="/z/d/drug information/142919.html" rel="external">nedosiran</a> are administered subcutaneously, and dosing is weight based. (See <a class="local">'Additional therapies for primary hyperoxaluria type 1'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplantation</strong> – In patients with PH type 1 disease and ESKD, the main options are combined liver-kidney transplantation or sequential liver and kidney transplantation. Until more data are available to better inform the choice, we perform combined liver-kidney transplantation. For patients who are <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> sensitive or have a late-onset form of the disease, isolated kidney transplantation is possible. (See <a class="local">'Transplantation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Danpure CJ. Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Nephrol Dial Transplant 1995; 10 Suppl 8:24.</a></li><li><a class="nounderline abstract_t">Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 2003; 18:986.</a></li><li><a class="nounderline abstract_t">Sas DJ, Enders FT, Mehta RA, et al. Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int 2020; 97:786.</a></li><li><a class="nounderline abstract_t">Hopp K, Cogal AG, Bergstralh EJ, et al. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J Am Soc Nephrol 2015; 26:2559.</a></li><li><a class="nounderline abstract_t">Takada Y, Kaneko N, Esumi H, et al. Human peroxisomal L-alanine: glyoxylate aminotransferase. Evolutionary loss of a mitochondrial targeting signal by point mutation of the initiation codon. Biochem J 1990; 268:517.</a></li><li><a class="nounderline abstract_t">Purdue PE, Lumb MJ, Fox M, et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991; 10:34.</a></li><li><a class="nounderline abstract_t">Devresse A, Cochat P, Godefroid N, Kanaan N. Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives. Kidney Int Rep 2020; 5:2136.</a></li><li><a class="nounderline abstract_t">Danpure CJ, Jennings PR, Fryer P, et al. Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity. J Inherit Metab Dis 1994; 17:487.</a></li><li><a class="nounderline abstract_t">Williams EL, Acquaviva C, Amoroso A, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 2009; 30:910.</a></li><li><a class="nounderline abstract_t">Rumsby G. Genetic defects underlying renal stone disease. Int J Surg 2016; 36:590.</a></li><li><a class="nounderline abstract_t">Perinpam M, Enders FT, Mara KC, et al. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin Biochem 2017; 50:1014.</a></li><li><a class="nounderline abstract_t">Seargeant LE, deGroot GW, Dilling LA, et al. Primary oxaluria type 2 (L-glyceric aciduria): a rare cause of nephrolithiasis in children. J Pediatr 1991; 118:912.</a></li><li><a class="nounderline abstract_t">Cregeen DP, Williams EL, Hulton S, Rumsby G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 2003; 22:497.</a></li><li><a class="nounderline abstract_t">Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009; 75:1264.</a></li><li><a class="nounderline abstract_t">Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013; 369:649.</a></li><li><a class="nounderline abstract_t">Riedel TJ, Knight J, Murray MS, et al. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 2012; 1822:1544.</a></li><li><a class="nounderline abstract_t">Hoppe B. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. Nephrol Dial Transplant 2012; 27:3024.</a></li><li><a class="nounderline abstract_t">Monico CG, Persson M, Ford GC, et al. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int 2002; 62:392.</a></li><li><a class="nounderline abstract_t">Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010; 87:392.</a></li><li><a class="nounderline abstract_t">Gee HY, Jun I, Braun DA, et al. Mutations in SLC26A1 Cause Nephrolithiasis. Am J Hum Genet 2016; 98:1228.</a></li><li><a class="nounderline abstract_t">Harambat J, Fargue S, Acquaviva C, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 2010; 77:443.</a></li><li><a class="nounderline abstract_t">Latta K, Brodehl J. Primary hyperoxaluria type I. Eur J Pediatr 1990; 149:518.</a></li><li><a class="nounderline abstract_t">Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005; 67:1704.</a></li><li><a class="nounderline abstract_t">Mandrile G, van Woerden CS, Berchialla P, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 2014; 86:1197.</a></li><li><a class="nounderline abstract_t">Cellini B, Montioli R, Paiardini A, et al. Molecular Insight into the Synergism between the Minor Allele of Human Liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I Mutation. J Biol Chem 2009; 284:8349.</a></li><li><a class="nounderline abstract_t">Tang X, Bergstralh EJ, Mehta RA, et al. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 2015; 87:623.</a></li><li><a class="nounderline abstract_t">Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.</a></li><li><a class="nounderline abstract_t">Cochat P, Deloraine A, Rotily M, et al. Epidemiology of primary hyperoxaluria type 1. Société de Néphrologie and the Société de Néphrologie Pédiatrique. Nephrol Dial Transplant 1995; 10 Suppl 8:3.</a></li><li><a class="nounderline abstract_t">Kopp N, Leumann E. Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant 1995; 10:2224.</a></li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS: 2008 Annual Report. Available at: https://web.emmes.com/study/ped/announce.htm (Accessed on October 19, 2010).</li><li><a class="nounderline abstract_t">Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol 2005; 25:290.</a></li><li><a class="nounderline abstract_t">Xie X, Zhang X. Primary Hyperoxaluria. N Engl J Med 2022; 386:976.</a></li><li><a class="nounderline abstract_t">Hoppe B. Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1. Kidney Int 2010; 77:383.</a></li><li><a class="nounderline abstract_t">Cochat P, Liutkus A, Fargue S, et al. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006; 21:1075.</a></li><li><a class="nounderline abstract_t">Millan MT, Berquist WE, So SK, et al. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 2003; 76:1458.</a></li><li><a class="nounderline abstract_t">Cochat P, Koch Nogueira PC, Mahmoud MA, et al. Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr 1999; 135:746.</a></li><li><a class="nounderline abstract_t">van Woerden CS, Groothoff JW, Wanders RJ, et al. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 2003; 18:273.</a></li><li><a class="nounderline abstract_t">Harambat J, van Stralen KJ, Espinosa L, et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 2012; 7:458.</a></li><li><a class="nounderline abstract_t">Amoroso A, Pirulli D, Florian F, et al. AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol 2001; 12:2072.</a></li><li><a class="nounderline abstract_t">Watts RW. Primary hyperoxaluria type I. QJM 1994; 87:593.</a></li><li><a class="nounderline abstract_t">Morgan SH, Purkiss P, Watts RW, Mansell MA. Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria. Nephron 1987; 46:253.</a></li><li><a class="nounderline abstract_t">Ben-Shalom E, Cytter-Kuint R, Rinat C, et al. Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study. Pediatr Nephrol 2021; 36:3123.</a></li><li><a class="nounderline abstract_t">Mookadam F, Smith T, Jiamsripong P, et al. Cardiac abnormalities in primary hyperoxaluria. Circ J 2010; 74:2403.</a></li><li><a class="nounderline abstract_t">Bacchetta J, Boivin G, Cochat P. Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 2016; 31:1.</a></li><li><a class="nounderline abstract_t">Small KW, Scheinman J, Klintworth GK. A clinicopathological study of ocular involvement in primary hyperoxaluria type I. Br J Ophthalmol 1992; 76:54.</a></li><li><a class="nounderline abstract_t">Bakshi NA, Al-Zahrani H. Bone marrow oxalosis. Blood 2012; 120:8.</a></li><li><a class="nounderline abstract_t">Frishberg Y, Feinstein S, Rinat C, Drukker A. Hypothyroidism in primary hyperoxaluria type 1. J Pediatr 2000; 136:255.</a></li><li class="breakAll">Coulter-Mackie, MB, White, CT, Hurley, RM, et al. Primary Hyperoxaluria Type 1. GeneReviews. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ph1 (Accessed on October 19, 2010).</li><li><a class="nounderline abstract_t">Blackmon JA, Jeffy BG, Malone JC, Knable AL Jr. Oxalosis involving the skin: case report and literature review. Arch Dermatol 2011; 147:1302.</a></li><li><a class="nounderline abstract_t">Garrelfs SF, Rumsby G, Peters-Sengers H, et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 2019; 96:1389.</a></li><li><a class="nounderline abstract_t">Johnson SA, Rumsby G, Cregeen D, Hulton SA. Primary hyperoxaluria type 2 in children. Pediatr Nephrol 2002; 17:597.</a></li><li><a class="nounderline abstract_t">Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001; 59:31.</a></li><li><a class="nounderline abstract_t">Singh P, Viehman JK, Mehta RA, et al. Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. Nephrol Dial Transplant 2022; 37:869.</a></li><li><a class="nounderline abstract_t">Fang X, He L, Xu G, et al. Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children. Pediatr Nephrol 2019; 34:1785.</a></li><li><a class="nounderline abstract_t">Beck BB, Baasner A, Buescher A, et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 2013; 21:162.</a></li><li><a class="nounderline abstract_t">Allard L, Cochat P, Leclerc AL, et al. Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr Nephrol 2015; 30:1807.</a></li><li><a class="nounderline abstract_t">Monico CG, Rossetti S, Belostotsky R, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 2011; 6:2289.</a></li><li><a class="nounderline abstract_t">Ventzke A, Feldkötter M, Wei A, et al. Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. Pediatr Nephrol 2017; 32:2263.</a></li><li><a class="nounderline abstract_t">Greed L, Willis F, Johnstone L, et al. Metabolite diagnosis of primary hyperoxaluria type 3. Pediatr Nephrol 2018; 33:1443.</a></li><li><a class="nounderline abstract_t">Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 2005; 25:154.</a></li><li><a class="nounderline abstract_t">Hoppe B, Latta K, von Schnakenburg C, Kemper MJ. Primary hyperoxaluria--the German experience. Am J Nephrol 2005; 25:276.</a></li><li><a class="nounderline abstract_t">Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012; 27:1729.</a></li><li><a class="nounderline abstract_t">Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2012; 8:467.</a></li><li><a class="nounderline abstract_t">Morgenstern BZ, Milliner DS, Murphy ME, et al. Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. J Pediatr 1993; 123:248.</a></li><li><a class="nounderline abstract_t">Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 1991; 66:501.</a></li><li><a class="nounderline abstract_t">von Schnakenburg C, Byrd DJ, Latta K, et al. Determination of oxalate excretion in spot urines of healthy children by ion chromatography. Eur J Clin Chem Clin Biochem 1994; 32:27.</a></li><li><a class="nounderline abstract_t">De Santo NG, Di Iorio B, Capasso G, et al. Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy). Pediatr Nephrol 1992; 6:149.</a></li><li><a class="nounderline abstract_t">Milliner DS, Cochat P, Hulton SA, et al. Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 2021; 36:1785.</a></li><li><a class="nounderline abstract_t">Hoppe B, Kemper MJ, Bökenkamp A, Langman CB. Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int 1998; 54:921.</a></li><li><a class="nounderline abstract_t">Shah RJ, Vaughan LE, Enders FT, et al. Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort. Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">Hillebrand P, Hoppe B. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function. Pediatr Nephrol 2020; 35:1227.</a></li><li><a class="nounderline abstract_t">Chlebeck PT, Milliner DS, Smith LH. Long-term prognosis in primary hyperoxaluria type II (L-glyceric aciduria). Am J Kidney Dis 1994; 23:255.</a></li><li><a class="nounderline abstract_t">Monico CG, Rossetti S, Schwanz HA, et al. Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. J Am Soc Nephrol 2007; 18:1905.</a></li><li><a class="nounderline abstract_t">Williams EL, Bagg EA, Mueller M, et al. Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing. Mol Genet Genomic Med 2015; 3:69.</a></li><li class="breakAll">Rumsby, G. Primary hyperoxaluria Type 2. Gene Reviews. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ph2.</li><li><a class="nounderline abstract_t">Danpure CJ. Molecular and clinical heterogeneity in primary hyperoxaluria type 1. Am J Kidney Dis 1991; 17:366.</a></li><li><a class="nounderline abstract_t">Witting C, Langman CB, Assimos D, et al. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol 2021; 16:487.</a></li><li><a class="nounderline abstract_t">Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 2021; 384:1216.</a></li><li><a class="nounderline abstract_t">Groothoff JW, Metry E, Deesker L, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 2023; 19:194.</a></li><li><a class="nounderline abstract_t">Hulton SA. The primary hyperoxalurias: A practical approach to diagnosis and treatment. Int J Surg 2016; 36:649.</a></li><li><a class="nounderline abstract_t">Milliner DS, Eickholt JT, Bergstralh EJ, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994; 331:1553.</a></li><li><a class="nounderline abstract_t">Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant 2005; 20:1525.</a></li><li><a class="nounderline abstract_t">Sikora P, von Unruh GE, Beck B, et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008; 73:1181.</a></li><li><a class="nounderline abstract_t">Fargue S, Harambat J, Gagnadoux MF, et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 2009; 76:767.</a></li><li class="breakAll">Cochat P, Collard LB. Primary hyperoxaluria. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004.</li><li><a class="nounderline abstract_t">Hoyer-Kuhn H, Kohbrok S, Volland R, et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol 2014; 9:468.</a></li><li><a class="nounderline abstract_t">Fargue S. Factors influencing clinical outcome in patients with primary hyperoxaluria type 1. Kidney Int 2014; 86:1074.</a></li><li><a class="nounderline abstract_t">Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 2013; 1832:1776.</a></li><li><a class="nounderline abstract_t">van Woerden CS, Groothoff JW, Wijburg FA, et al. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 2004; 66:746.</a></li><li><a class="nounderline abstract_t">Rumsby G, Williams E, Coulter-Mackie M. Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Kidney Int 2004; 66:959.</a></li><li><a class="nounderline abstract_t">Liebow A, Li X, Racie T, et al. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol 2017; 28:494.</a></li><li><a class="nounderline abstract_t">Milliner DS. siRNA Therapeutics for Primary Hyperoxaluria: A Beginning. Mol Ther 2016; 24:666.</a></li><li><a class="nounderline abstract_t">Wood KD, Holmes RP, Knight J. RNA interference in the treatment of renal stone disease: Current status and future potentials. Int J Surg 2016; 36:713.</a></li><li><a class="nounderline abstract_t">Jaklevic MC. First Drug Approved for Rare Genetic Disorder Affecting Kidneys. JAMA 2021; 325:214.</a></li><li class="breakAll">US Food and Drug Administration. FDA approval of lumasiran for treatment of primary hyperoxaluria type 1. 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder (Accessed on November 24, 2020).</li><li><a class="nounderline abstract_t">Frishberg Y CP, Vant Hoff W, Hulton S, et al. A phase 1/2 trial of Lumasiran (ALN-GO1), an investigational RNA interference (RNAI) therapeutic for primary hyperoxaluria type. Pediatr Nephrol 2018; 33:1807.</a></li><li><a class="nounderline abstract_t">Sas DJ, Magen D, Hayes W, et al. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genet Med 2022; 24:654.</a></li><li><a class="nounderline abstract_t">Hayes W, Sas DJ, Magen D, et al. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol 2023; 38:1075.</a></li><li><a class="nounderline abstract_t">Michael M, Groothoff JW, Shasha-Lavsky H, et al. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. Am J Kidney Dis 2023; 81:145.</a></li><li><a class="nounderline abstract_t">Baum MA, Langman C, Cochat P, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 2023; 103:207.</a></li><li class="breakAll">Manufacturer's prescibing information for RIFLOZA, October 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf (Accessed on October 08, 2023).</li><li><a class="nounderline abstract_t">Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69:691.</a></li><li><a class="nounderline abstract_t">Hatch M, Gjymishka A, Salido EC, et al. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011; 300:G461.</a></li><li><a class="nounderline abstract_t">Hoppe B, Niaudet P, Salomon R, et al. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol 2017; 32:781.</a></li><li><a class="nounderline abstract_t">Hoppe B, Groothoff JW, Hulton SA, et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011; 26:3609.</a></li><li><a class="nounderline abstract_t">Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis 2018; 46:313.</a></li><li><a class="nounderline abstract_t">Hoppe B, Pellikka PA, Dehmel B, et al. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study. Nephrol Dial Transplant 2021; 36:1464.</a></li><li><a class="nounderline abstract_t">Arvans D, Jung YC, Antonopoulos D, et al. Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells. J Am Soc Nephrol 2017; 28:876.</a></li><li><a class="nounderline abstract_t">Miyata N, Steffen J, Johnson ME, et al. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci U S A 2014; 111:14406.</a></li><li><a class="nounderline abstract_t">Le Dudal M, Huguet L, Perez J, et al. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J Clin Invest 2019; 129:2571.</a></li><li><a class="nounderline abstract_t">Martin-Higueras C, Feldkötter M, Hoppe B. Is stiripentol truly effective for treating primary hyperoxaluria? Clin Kidney J 2021; 14:442.</a></li><li><a class="nounderline abstract_t">Wyatt CM, Drüeke TB. Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int 2020; 97:17.</a></li><li><a class="nounderline abstract_t">Grateau G, Grünfeld JP, Beurton D, et al. Post-surgical deterioration of renal function in primary hyperoxaluria. Nephrol Dial Transplant 1987; 1:261.</a></li><li><a class="nounderline abstract_t">Al-Abadi E, Hulton SA. Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis--still the first choice? Pediatr Nephrol 2013; 28:1085.</a></li><li><a class="nounderline abstract_t">Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis 2001; 37:233.</a></li><li><a class="nounderline abstract_t">Carrasco A Jr, Granberg CF, Gettman MT, et al. Surgical management of stone disease in patients with primary hyperoxaluria. Urology 2015; 85:522.</a></li><li><a class="nounderline abstract_t">Illies F, Bonzel KE, Wingen AM, et al. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 2006; 70:1642.</a></li><li><a class="nounderline abstract_t">Hoppe B, Graf D, Offner G, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 1996; 10:488.</a></li><li><a class="nounderline abstract_t">Marangella M, Petrarulo M, Cosseddu D, et al. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 1992; 19:546.</a></li><li><a class="nounderline abstract_t">Hoppe B, Kemper MJ, Bökenkamp A, et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999; 56:268.</a></li><li><a class="nounderline abstract_t">Bergstralh EJ, Monico CG, Lieske JC, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant 2010; 10:2493.</a></li><li><a class="nounderline abstract_t">Scheinman JI. Liver transplantation in oxalosis prior to advanced chronic kidney disease. Pediatr Nephrol 2010; 25:2217.</a></li><li><a class="nounderline abstract_t">Metry EL, Garrelfs SF, Peters-Sengers H, et al. Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry. Kidney Int Rep 2022; 7:210.</a></li><li><a class="nounderline abstract_t">Filler G, Hoppe B. Combined liver-kidney transplantation for hyperoxaluria type II? Pediatr Transplant 2014; 18:237.</a></li><li><a class="nounderline abstract_t">Naderi G, Latif A, Tabassomi F, Esfahani ST. Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. Pediatr Transplant 2014; 18:E69.</a></li><li><a class="nounderline abstract_t">Dhondup T, Lorenz EC, Milliner DS, Lieske JC. Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report. Am J Transplant 2018; 18:253.</a></li><li><a class="nounderline abstract_t">Del Bello A, Cointault O, Delas A, Kamar N. Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation. Am J Transplant 2020; 20:1752.</a></li><li><a class="nounderline abstract_t">Jeyarajah DR, McBride M, Klintmalm GB, Gonwa TA. Combined liver-kidney transplantation: what are the indications? Transplantation 1997; 64:1091.</a></li><li><a class="nounderline abstract_t">Brinkert F, Ganschow R, Helmke K, et al. Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation 2009; 87:1415.</a></li><li><a class="nounderline abstract_t">Compagnon P, Metzler P, Samuel D, et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl 2014; 20:1475.</a></li><li><a class="nounderline abstract_t">Metry EL, van Dijk LMM, Peters-Sengers H, et al. Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr Nephrol 2021; 36:2217.</a></li><li><a class="nounderline abstract_t">Lee E, Ramos-Gonzalez G, Rodig N, et al. Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver-kidney transplantation for primary hyperoxaluria type 1. Pediatr Nephrol 2018; 33:881.</a></li><li><a class="nounderline abstract_t">Malla I, Lysy PA, Godefroid N, et al. Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation. Pediatr Transplant 2009; 13:782.</a></li><li><a class="nounderline abstract_t">Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 2010; 15:590.</a></li><li><a class="nounderline abstract_t">Sasaki K, Sakamoto S, Uchida H, et al. Two-step transplantation for primary hyperoxaluria: a winning strategy to prevent progression of systemic oxalosis in early onset renal insufficiency cases. Pediatr Transplant 2015; 19:E1.</a></li><li><a class="nounderline abstract_t">Kemper MJ. Concurrent or sequential liver and kidney transplantation in children with primary hyperoxaluria type 1? Pediatr Transplant 2005; 9:693.</a></li><li><a class="nounderline abstract_t">Shasha-Lavsky H, Avni A, Paz Z, et al. Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1. Pediatr Nephrol 2023; 38:1811.</a></li><li><a class="nounderline abstract_t">Gruessner RW. Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I. N Engl J Med 1998; 338:1924.</a></li><li><a class="nounderline abstract_t">Galanti M, Contreras A. Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1. Pediatr Nephrol 2010; 25:2359.</a></li><li><a class="nounderline abstract_t">Cochat P, Schärer K. Should liver transplantation be performed before advanced renal insufficiency in primary hyperoxaluria type 1? Pediatr Nephrol 1993; 7:212.</a></li><li><a class="nounderline abstract_t">Kemper MJ. The role of preemptive liver transplantation in primary hyperoxaluria type 1. Urol Res 2005; 33:376.</a></li><li><a class="nounderline abstract_t">Perera MT, Sharif K, Lloyd C, et al. Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration. Nephrol Dial Transplant 2011; 26:354.</a></li><li><a class="nounderline abstract_t">Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 2013; 28:2273.</a></li><li><a class="nounderline abstract_t">Squires J, Nguyen C. Complexity of pre-emptive liver transplantation in children with primary hyperoxaluria type 1. Pediatr Transplant 2016; 20:604.</a></li><li><a class="nounderline abstract_t">Broyer M, Brunner FP, Brynger H, et al. Kidney transplantation in primary oxalosis: data from the EDTA Registry. Nephrol Dial Transplant 1990; 5:332.</a></li><li><a class="nounderline abstract_t">Müller T, Sikora P, Offner G, et al. Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center. Clin Nephrol 1998; 49:82.</a></li><li><a class="nounderline abstract_t">Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.</a></li><li><a class="nounderline abstract_t">Lorenz EC, Lieske JC, Seide BM, et al. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 2014; 14:1433.</a></li></ol></div><div id="topicVersionRevision">Topic 6141 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592621" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920626" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32093915" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644115" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2363689" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human peroxisomal L-alanine: glyoxylate aminotransferase. Evolutionary loss of a mitochondrial targeting signal by point mutation of the initiation codon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2045108" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305106" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967498" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479957" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838384" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Genetic defects underlying renal stone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28764885" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2040928" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary oxaluria type 2 (L-glyceric aciduria): a rare cause of nephrolithiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14635115" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225556" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The primary hyperoxalurias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23944302" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22771891" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851625" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110000" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20797690" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mutations in DHDPSL are responsible for primary hyperoxaluria type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27210743" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mutations in SLC26A1 Cause Nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016466" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189732" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary hyperoxaluria type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840016" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24988064" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155213" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular Insight into the Synergism between the Minor Allele of Human Liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25229337" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972657" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Estimating prevalence in single-gene kidney diseases progressing to renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592622" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiology of primary hyperoxaluria type 1. Sociétéde Néphrologie and the Sociétéde Néphrologie Pédiatrique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808215" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changing pattern of primary hyperoxaluria in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808215" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Changing pattern of primary hyperoxaluria in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15961949" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : International registry for primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35245013" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Primary Hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150937" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16810517" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary hyperoxaluria type 1: still challenging!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657686" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586179" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary hyperoxaluria in infants: medical, ethical, and economic issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543880" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223608" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11562405" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7987654" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Primary hyperoxaluria type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306417" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33651179" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921818" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiac abnormalities in primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631241" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bone impairment in primary hyperoxaluria: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739695" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A clinicopathological study of ocular involvement in primary hyperoxaluria type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22953330" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bone marrow oxalosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10657836" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypothyroidism in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10657836" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hypothyroidism in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768445" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Oxalosis involving the skin: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31685312" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12185464" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Primary hyperoxaluria type 2 in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135054" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33543760" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31123811" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781098" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972204" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Renal function can be impaired in children with primary hyperoxaluria type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21896830" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28711958" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29705963" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metabolite diagnosis of primary hyperoxaluria type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855742" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The primary hyperoxalurias: an algorithm for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15961947" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Primary hyperoxaluria--the German experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547750" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688746" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An update on primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345420" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031609" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Urinary oxalate and glycolate excretion and plasma oxalate concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8167190" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Determination of oxalate excretion in spot urines of healthy children by ion chromatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571211" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33515281" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734617" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443777" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32274573" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311084" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term prognosis in primary hyperoxaluria type II (L-glyceric aciduria).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460142" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629080" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629080" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2008900" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Molecular and clinical heterogeneity in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32900691" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pathophysiology and Treatment of Enteric Hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33789010" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36604599" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27815184" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The primary hyperoxalurias: A practical approach to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969325" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956068" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Primary hyperoxaluria: from gene defects to designer drugs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337715" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571789" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571789" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24385516" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427081" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Factors influencing clinical outcome in patients with primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23597595" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253729" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical implications of mutation analysis in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327387" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27432743" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27081720" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : siRNA Therapeutics for Primary Hyperoxaluria: A Beginning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27847291" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : RNA interference in the treatment of renal stone disease: Current status and future potentials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464323" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : First Drug Approved for Rare Genetic Disorder Affecting Kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464323" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : First Drug Approved for Rare Genetic Disorder Affecting Kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A phase 1/2 trial of Lumasiran (ALN-GO1), an investigational RNA interference (RNAI) therapeutic for primary hyperoxaluria type</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34906487" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35913563" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843439" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36007597" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36007597" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518326" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21163900" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27924398" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460356" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28718073" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810261" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27738124" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25237136" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30946030" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33564453" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Is stiripentol truly effective for treating primary hyperoxaluria?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31451300" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110687" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Post-surgical deterioration of renal function in primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23397522" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis--still the first choice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157364" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Risk for renal failure in nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733260" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Surgical management of stone disease in patients with primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16955107" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8865249" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595703" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411702" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20849551" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Transplantation outcomes in primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20686903" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Liver transplantation in oxalosis prior to advanced chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35155860" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708351" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Combined liver-kidney transplantation for hyperoxaluria type II?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24597735" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28681512" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090455" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9355821" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Combined liver-kidney transplantation: what are the indications?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19424045" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267365" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33830344" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29243158" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver-kidney transplantation for primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032423" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733487" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Primary hyperoxaluria type 1: strategy for organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25323048" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Two-step transplantation for primary hyperoxaluria: a winning strategy to prevent progression of systemic oxalosis in early onset renal insufficiency cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269037" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Concurrent or sequential liver and kidney transplantation in children with primary hyperoxaluria type 1?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36449101" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643991" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628764" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476723" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Should liver transplantation be performed before advanced renal insufficiency in primary hyperoxaluria type 1?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284878" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The role of preemptive liver transplantation in primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573805" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23494551" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Primary hyperoxaluria type 1: practical and ethical issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27292943" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Complexity of pre-emptive liver transplantation in children with primary hyperoxaluria type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2115623" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Kidney transplantation in primary oxalosis: data from the EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9524777" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275969" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797341" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
